| Expression pattern: |
UP |
| Associated gene: |
AGO2, TP53 |
| Associated microRNA: |
- |
| Biological function: |
Promotes CLL cell proliferation/viability, inhibits apoptosis, and modulates mitochondrial function; its silencing enhances anti-tumor drug effects. |
| Molecular mechanism: |
Does not act as a ceRNA (fails to bind AGO2); influences mitochondrial membrane potential and ATP production; mitochondrial-targeting compounds reduce mc-COX2 biogenesis and synergize with mc-COX2 knockdown. |
| Biological pathway or process: |
mitochondrial function (other); proliferation (promotes); apoptosis (inhibits); drug resistance (inhibits) |
| Detected method: |
Q
B
H
M
|
| Validation methods: |
Microarray; RT-qPCR; FISH / smFISH; Northern Blot; Back-Splice Junction PCR / divergent primers PCR; Sanger Sequencing; RNase R Treatment; Actinomycin D / DRB Stability Assay; RIP (RNA Immunoprecipitation); Transfection; CCK8; Annexin V/PI Flow Cytometry; In Vivo Animal Model; Western Blot; Survival Analysis; Clinical Sample Validation; Bioinformatics Analysis |
| Clinical significance: |
High plasma/exosomal mc-COX2 predicts worse overall survival in CLL patients and is proposed as a prognostic biomarker/liquid biopsy target. |
| Description: |
mc-COX2 (hsa_circ_0089762), an mt-circRNA derived from mitochondrial COX2, is up-regulated in CLL plasma and enriched in plasma exosomes. mc-COX2 promotes CLL cell viability/proliferation, supports mitochondrial function, and inhibits apoptosis; high mc-COX2 is associated with worse overall survival. Mechanistically, mc-COX2 does not bind AGO2 and may act through non-ceRNA mechanisms; targeting mc-COX2 enhances responses to mitochondrial-related compounds and inhibitors. |
| Confidence score: |
0.8478 |